A double-blind , randomized , placebo-controlled , multicenter trial of 18 months ' duration was conducted in 512 subjects , with probable or definite ALS and a slow vital capacity ( SVC ) 70 % , receiving 330 mg olesoxime daily or matching placebo and 50 mg riluzole twice a day in all .